

invitation



Dear Colleagues,

we are pleased to invite you to attend our Luncheon-Symposium entitled "RLS and Parkinson's Disease - What's new?" At this meeting two experts on Restless Legs Syndrome (RLS) and Parkinson's Disease (PD) will review diagnostic and therapeutic tools and discuss new developments in RLS and PD.

Yours sincerely

**Dr. Antje Müller-Schubert**  
Medical Relations  
Axxonis Pharma AG  
Schöneberger Straße 15  
10963 Berlin

Luncheon-Symposium  
Congress Center Würzburg, Barbarossa-Saal, Sunday 3rd June 2007 13.30 – 15.00

**RLS AND PARKINSON'S DISEASE – WHAT IS NEW?**

Chairman:  
Prof. Peter Riederer

Speakers:  
13.30-14.15:  
Prof. R. Kohnen:  
*"New Developments in RLS, Diagnosis, Therapy and Research"*

14.15-15.00:  
Dr. R. Horowski:  
*"Parkinson's Disease, transdermal Lisuride and other new developments."*

Poster-Session,  
Foyer Maritim-Hotel:  
Sunday 3rd June 2007  
15.00-16.00

No. DP-01-04  
KP Latté, B Schurad, R Horowski:

*"Lisuride, a dopamine agonist, is a potent serotonin 5-HT2B receptor antagonist and is not connected to valvular heart disease"*



**Prof. Dr. Ralf Kohnen:**

Ralf Kohnen is managing director of IMEREM Nürnberg, a CRO specialized for CNS indications and responsible for more than 300 clinical trials in this field. He is lecturing as an associate professor for clinical psychology at the University of Erlangen-Nürnberg. Ralf Kohnen is member of several associations, e.g., Association of Neuropsychopharmacology and Pharmacopsychiatry (AGNP); European College of Neuropsychopharmacology (ECNP); German Society of Biological Psychiatry; German Society of Sleep Research and Sleep Medicine (DGSM) and the World Association of Sleep Medicine (WASM); the European (EURLSSG) and the International Restless Legs Study Group (IRLSSG), biometrical and psychological associations and several working groups. He has published more than 150 peer review papers in international journals.



**Reinhard Horowski, MD:**

CMO/CSO of Axxonis Pharma AG (formerly NeuroBiotec GmbH); Arzt für Pharmakologie  
Since 1975 Department Head with responsibility for clinical studies, more than 20 Phase I and 80 clinical studies. 170 publications and 80 contributions to conferences, co-founder and board member of the International Winter Conference on Neurodegeneration, honorary member of the Austrian and German Parkinson Societies.



**Prof. Dr. Peter F. Riederer:**

Head of the Clinical Neurochemistry Department at the Psychiatric Hospital, University of Würzburg. He is the author of pivotal research in the field of neurodegenerative diseases where he has published more than 950 original articles and coauthored several books. He is editor of the Journal of Neural Transmission and member of the editorial or advisory board of many other leading journals in the field. He is honorary president of the German Parkinson Society, was president and organizer of the 16th International Parkinson Congress in Berlin 2005 and of many other important international conventions and has received many international honours.

Luncheon-Symposium der Axxonis Pharma AG  
Congress Center Würzburg, Barbarossa-Saal,  
Sunday 3rd June 2007 13.30 – 15.00

## RLS AND PARKINSON'S DISEASE – WHAT IS NEW?

**Professor Dr. Ralf Kohnen:**

### ***New Developments in RLS, Diagnosis, Therapy and Research***

In the last decade, scientific research in Restless Legs Syndrome (RLS) has escalated. This presentation summarizes the most important progress and gives an overview on state of the art in RLS. Starting with the definition of RLS as a "movement-responsive quiescent nocturnal focal akathisia usually with dysesthesias" new approaches for standardized diagnostic and differential diagnostic assessments are presented and opposed to experiences from large epidemiological trials in RLS. New pathophysiological thoughts and genetic findings are sketched. The results of a series of large-scale clinical trials are described and conclusions drawn on treatment options. In this context, treatment complications like augmentation, tolerance, or rebound are discussed. The presentation closes with an outline of future research in RLS.

**Dr. Reinhard Horowski:**

### ***Parkinson's Disease, transdermal Lisuride and other new developments***

Parkinson's Disease has become a great success story since Birkmayer and colleagues first introduced levodopa as well as decarboxylase and MAO-B inhibitors (selegiline, together with Riederer and Youdim). Levodopa and its enhancers nowadays are complemented by dopamine agonists which will be reviewed. Continuous dopaminergic stimulation (CDS) has become a major therapeutic target, which can be achieved, e.g., with parenteral forms of lisuride (patch, minipump). Newest therapeutic results which show a combination of strong and longlasting dopamine agonist effects with ease of administration and very few general side effects will be presented. Fortunately lisuride as a potent 5-HT<sub>2B</sub> antagonist appears to be devoid of cardiac side effects (valvulopathies) and thus parenteral lisuride products can be expected to improve the therapeutic choices for PD patients.